However, in real life, IDO inhibitors are unlikely to be used as monotherapy; furthermore, our model of active TB, while beneficial for the evaluation of vaccines and therapeutics, requires exposure to a nonphysiological high dose of M. tuberculosis for infection and may not represent a real-life situation. Here, IDO1 is linked to infection.